# A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease

> **NCT00645190** · PHASE3 · COMPLETED · sponsor: **Xian-Janssen Pharmaceutical Ltd.** · enrollment: 215 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Galantamine HBr

## Key facts

- **NCT ID:** NCT00645190
- **Lead sponsor:** Xian-Janssen Pharmaceutical Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-02
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645190, "A Randomized, Double-blind, Flexible Dose, Multicenter Study to Evaluate the Effectiveness and Safety of Galantamine IR in Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00645190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*